INVESTOR/MEDICAL BREAKTHROUGH TYPE-II DIABETES
A new Type-II Diabetes drug continues to help both the investor and the medical communities. Chosen in 1998 as DRUG OF THE YEAR in CHINA, world wide medical communities feel the DIAB-II drug is a revolutionary treatment for Type-II diabetes.DIAB-II has no serious contraindications, it sensitizes glucose faster and continues to build up muscle cells-not fat cells. IMMUNIS Corp. (IMMC-OTCBB) has a 25% interest in the profit of all sales outside of China. IMMC derives its revenue from BiOTECH LIMITED, the developer of DIAB-II, which in turn sell/market this drug to their customers biotechltd.com). IMMC has NO DEBT, 600,000 shares PUBLIC FLOAT, Nominal Overhead, No capital expenditures & Averages a 60% margin. BiOTECH'a Strong World wide medical supporters and on-going Distribution/Marketing agreements throughout Latin America enables IMMC to earn substantial returns with little risk. The December 21 issue of Fortune Magazine said: "Pharmaceutical companies are almost unique in their ability to generate strong earnings growth in any economic climate".The same article reported that many Wall Street Analysts, (http://www.wallstreetresearch.net/IMMC/report.html), are excited about any type of new drug with empirical evidence. IMMC has many investors, analysts, pharmacists, and doctors excited about this company and DIAB-II's EXTRAORDINARY ABILITIES. IMMC currently trades at 2.25 and continues to appreciate in price! |
